Abstracts



Abstracts are presentation of research at Academic meetings

* denotes prize or grant awarded for poster presentation

  1. R. Srirajaskanthan, A. Ahmed, J.K Ramage. Does the TNM staging criteria predict survival in patients with small bowel neuroendocrine tumours. Digestive diseases Federation Meeting 2012

  2. R. Srirajaskanthan, J.K Ramage, A. Ahmed. Survival and Recurrent disease in patients with resected small bowel neuroendocrine tumours. Digestive diseases Federation Meeting 2012.

  3. R. Srirajaskanthan, A.Ahmed, P. Srinivasan, N. Heaton, J.K Ramage. Survival and cause of death in patients with small bowel neuroendocrine tumours. European Neuroendocrine Tumour Society  (ENETS) 2012.

  4. R. Srirajaskanthan, N. Jervis, A. Ahmed, A. O’Sullivan, P. Srinivasan, A. Prachialis, J.K Ramage. Does the TNM staging classification predict survival in patients with small bowel neuroendocrine tumours (NETs). ENETS 2012.

  5. R. Srirajaskanthan, A. Ahmed, A. O’Sullivan, A. Prachialis, J.K Ramage. Resection of primary tumour improves survival in small bowel NETs: a single centre experience. ENETS 2012.

  6. R. Srirajaskanthan, A. Ahmed, J.K Ramage. How long to continue surveillance in patients following ‘curative resection’ of primary small bowel tumours. ENETS 2012.

  7. R. Srirajaskanthan, A.Ahmed, P. Srinivasan, N. Heaton, J.K Ramage. Survival and cause of death in patients with small bowel neuroendocrine tumours. UKINETS 2011.

  8. R. Srirajaskanthan, N. Jervis, A. Ahmed, A. O’Sullivan, P. Srinivasan, A. Prachialis, J.K Ramage. Does the TNM staging classification predict survival in patients with small bowel NETs. United Kingdom and Ireland Neuroendocrine tumour Society UKINETS 2011. full

  9. R. Srirajaskanthan, A. Ahmed, A. O’Sullivan, A. Prachialis, J.K Ramage. Resection of primary tumour improves survival in small bowel NETs: a single centre experience. UKINETS 2011.

  10. R. Srirajaskanthan, N. Jervis, J.K. Ramage. Rare sites of primary neuroendocrine tumours and metastases. UKINETS 2011.

  11. R. Srirajaskanthan, N. Mulholland, A. Ahmed, N. Jervis, J.K Ramage. Clinical presentation and diagnostic features of small bowel NETs: A single centre experience. UKINETS 2011.

  12. R. Srirajaskanthan, A. Ahmed, J.K Ramage. How long to continue surveillance in patients following ‘curative resection’ of primary small bowel tumours. UKINETS 2011.

  13. R. Srirajaskanthan, J.K. Ramage. Late presentation of liver metastases: 50 years after resection of a primary small bowel neuroendocrine tumour. Issues for follow-up. UKINETS, 2010.

  14. C. G. Antoniades; M. J. Bruce; M. McPhail; R. Srirajaskanthan; P. A. Berry; M. J. Hussain; C. Willars; W. Bernal; G. Auzinger; J. Wendon.  Cytokine biomarker profiling in acetaminophen-induced acute liver failure: importance of monocyte chemotactic protein-1 in prognosis and hepatic encephalopathy. AASLD 2010.

  15. C. G. Antoniades; M. J. Bruce; M. McPhail; R. Srirajaskanthan; P. A. Berry; M. J. Hussain; C. Willars; W. Bernal; G. Auzinger; J. Wendon.  Cytokine biomarker profiling in acetaminophen-induced acute liver failure: importance of monocyte chemotactic protein-1 in prognosis and hepatic encephalopathy.  BASL 2010

  16. R. Srirajaskanthan, S. Soni, S. Alexander, S.B Lucas, T. Wong, and J.A White Lymphogranuloma venereum proctitis masquerading as inflammatory bowel disease in 12 homosexual men. BSG, 2010

  17. R. Srirajaskanthan, D. Borrow, S. Anderson. Simethicone improves mucosal visualisation in small bowel capsule endoscopy. UEGW/ WGO 2009

  18. R. Srirajaskanthan, D. Barrow, S. Anderson. Bowel preparation improves mucosal visualisation in patients undergoing small bowel capsule enteroscopy. UEGW/ WGO 2009

  19. R. Srirajaskanthan, R. Conn, C.Bulwer, P. Irving. The Blatchford scoring system enables accurate risk stratification of patients with upper gastrointestinal haemorrhage. UEGW/WGO 2009

  20. R. Srirajaskanthan, D. Barrow, S. Anderson. Small bowel capsule endoscopy rarely alters management in patients with non-specific abdominal pain. UEGW/WGO 2009

  21. R.Srirajaskanthan, M. Caplin, M. Waugh, J.Watkins, T.Meyer, J.J Hsuan, N.J. Beaumont. Novel biomarkers in the diagnosis of Neuroendocrine Tumours. UEGF Basic science and cell signaling conference, 2009.

  22. R. Srirajaskanthan, K. Desai, A. Jayaratnam, E. Carras, C. Toumpanakis, T. Meyer, M. Caplin. Uncommon sites for metastasis of neuroendocrine tumour in adults.  ASCO 2009; 27: e15683

  23. K. Desai, R. Srirajaskanthan, T. Singharo, L. Morgan-Rowe, M.E Caplin. Analysis of association between carcinoid heart disease and mesenteric fibrosis in patients with midgut carcinoid tumour. ASCO 2009; 27: e15650

  24. C. Toumpanakis, A. Quigley, R. Srirajaskanthan, L. Marelli, T, J. Buscombe, M. E. Caplin. 90-Yttrium-DOTA-octreotate for the treatment of advanced neuroendocrine tumors.  ASCO 2009; 27:4594

  25. R. Srirajaskanthan, C. Toumpanakis, B. Warner, S. Subash, M.E Caplin. Prognostic factors in Gastroenteropancreatic Neuroendocrine Tumours. Gut 2009; 58: A152

  26. R.Srirajaskanthan, K.Desai, C. Toumpanakis, Amaki, A. Krepska, L. Marelli, M. Winslet, G.Ogunbyi, M. Caplin. Mesenteric fibrosis in patients with small bowel carcinoid tumours: impact on quality of life and survival. Gut 2009; 58

  27. R. Srirajaskanthan, C. Toumpanakis, B. Warner, S. Subash, M.E Caplin. Prognostic factors in midgut  neuroendocrine Tumours. ENETS 2009

  28. R. Srirajaskanthan, K. Desai, T. Meyer, M.E Caplin. Uncommon sites for metastasis of neuroendocrine tumours in adults. ENETS 2009.

  29. K. Desai, R. Srirajaskanthan, T. Singharo, L. Morgan-Rowe, M.E Caplin.  Analysis of association between carcinoid heart disease and mesenteric fibrosis in patients with midgut carcinoid tumour. ENETS 2009

  30. *R. Srirajaskanthan, G. Darcy, T. Meyer, M.E Caplin. Angiopoeitin-2 expression is upregulated in the serum of patients with gastroenteropancreatic neuroendocrine tumours. UKINETS 2008 (1st prize)

  31. R. Srirajaskanthan, C. Toumpanakis, B. Warner, S. Subash, M.E Caplin. Prognostic factors in Gastroenteropancreatic Neuroendocrine Tumours. UKINETS 2008

  32. *R. Srirajaskanthan, C. Toumpanakis, Amaki, A. Krepska, L. Marelli, M. Winslet, G.Ogunbyi, M. Caplin. Mesenteric fibrosis in patients with small bowel carcinoid tumours: impact on quality of life and survival. UEGW 2008 (awarded travel grant)

  33. R. Srirajaskanthan, G. Darcy, T. Meyer, M.E Caplin. Angiopoeitin-2 expression is upregulated in the serum of patients with gastroenteropancreatic neuroendocrine tumours. UEGW 2008.

  34. Bellay Oscura
  35. R. Srirajaskanthan, L. Marelli, A. Karpathakis, C. Toumpanakis, T. Meyer, J. Buscombe, M.Dusmet, M.E.Caplin. Bronchial carcinoid tumours: Clinical features and management in a series of 45 patients. J Clin Oncol 26: 2008 suppl; abstr 19076

  36. R. Srirajaskanthan, J. Watkins, M.E Caplin. Co-expression of somatostatin and dopamine receptors in neuroendocrine tumours, an immunohistochemical study. DDW 2008. Gastroenterology 34; 4:A-299

  37. R. Srirajaskanthan, J. Soh, AM Quigley, C. Toumpanakis, J. Buscombe, M.E Caplin. Comparison of 68Ga-Octreotate-PET and (111In)-pentetreotide scintigraphy (OctreoscanTM)-Spect in Patients with Neuroendocrine Tumours. DDW 2008, Gastroenterology 134;4:A-299

  38. R. Srirajaskanthan, T. Shah, J. Watkins, L. Marelli, A. Quaglia, K. Khan, R. Sim, D. Hochhauser, M.E Caplin. The expression ErbB family of receptors (EGRF, HER-2, HER-3 and HER-4) in Neuroendocrine Tumours. DDW, 2008. Gastroenterology 34; 4:A-299

  39. AM. Quigley, R. Srirajaskanthan, M.E Caplin, J. Bomanji, J. Buscombe. Planning therapy for NET: In-111 pentetreotide or Ga-68 DOTATATE PET/CT? J. Nucl. Med. 49:321P

  40. A-M Quigley, R Srirajaskanthan, J Bomangi, ME Caplin, PJ Ell. Comparison of 68-Ga Dota-Octreotate PET and 18-FDG PET in patients with neuroendocrine tumours. BNMS 2008.

  41. E. Nowosinska, A.M Quigley, R. Srirajaskanthan, M.E Caplin, J. Buscombe, A.J Hilson. 111In-pentetreotide and 99mTc- MDP Bone Scintigraphy in the Identification of Bone Metastasis: Correlation with Tumour Grade and Survival in Patients with Neuroendocrine Tumours. BNMS 2008.

  42. T Shah, R Srirajaskanthan, M Bhogal, C Toumpanakis, T Meyer, A Noonan, C Witney-Smith, T Amin, P Bhogal, N Sivathasan, B Warner, D Hochhauser, M.E Caplin. Alpha fetoprotein and human chorionic gonadotrophin-β are prognostic tumour markers in patients with neuroendocrine tumours. DDW 2008; Gastroenterology; 134; 4: A-299

  43. L. Marelli, C. Toumpanakis, R. SriRajaskanthan, T. Eves, J. Watkins, M. Caplin. Assessment and outcomes in gastric carcinoid. DDW 2008, Gastroenterology; 134; 4:A-298

  44. R. Srirajaskanthan, T. Shah, J. Watkins, L. Marelli, A. Quaglia, K. Khan, R. Sim, D. Hochhauser, M.E Caplin. The expression ErbB family of receptors (EGRF, HER-2, HER-3 and HER-4) in Neuroendocrine Tumours. BSG, 2008

  45. R. Srirajaskanthan; A. Krepska;L. Marelli, N. Mendes, A.; Davidson;C. Toumpanakis; T. Meyer; A. Mayer; M. Caplin. Management and prognostic factors in Pancreatic Endocrine Tumours. BSG 2008

  46. L. Marelli, C. Toumpanakis, R. Srirajaskanthan, T. Eves, J. Watkins, M. Caplin. Assessment and outcomes in gastric carcinoid. BSG 2008

  47. T Shah, R Srirajaskanthan, M Bhogal, C Toumpanakis, T Meyer, A Noonan, C Witney-Smith, T Amin, P Bhogal, N Sivathasan, B Warner, D Hochhauser, M.E Caplin. Alpha fetoprotein and human chorionic gonadotrophin-β are prognostic tumour markers in patients with neuroendocrine tumours. BSG 2008

  48. R. Srirajaskanthan, J. Watkins, M.E Caplin. Co-expression of somatostatin and dopamine receptors in neuroendocrine tumours, an immunohistochemical study. ENETS 2008.

  49. R. Srirajaskanthan, M. McStay, C. Toumpanakis, T. Meyer, M.E Caplin. Clinical features and management of Parathyroid hormone related peptide secreting pancreatic neuroendocrine tumours. ENETS 2008.

  50. R. Srirajaskanthan, J. Soh, A.M Quigley, C. Toumpanakis, J. Buscombe, M.E Caplin. Comparison of 68Ga-Octreotate-PET and (111In)-pentetreotide scintigraphy (OctreoscanTM)-Spect in Patients with Neuroendocrine Tumours. ENETS 2008

  51. L. Marelli, C. Toumpanakis, R. Srirajaskanthan, T. Eves, J. Watkins, M. Caplin. Assessment and outcomes in gastric carcinoid. ENETS, 2008

  52. R. Srirajaskanthan, M. McStay, C.Toumpanakis, T. Meyer, M.E Caplin. Clinical features and management of Parathyroid hormone related peptide secreting pancreatic neuroendocrine tumours. UKINET 2007.

  53. R. Srirajaskanthan; A. Krepska; L. Marelli, N. Mendes, A.; Davidson; C. Toumpanakis; T. Meyer; A. Mayer; M. Caplin. Management and prognostic factors in Pancreatic Endocrine Tumours. UKINET 2007

  54. *R. Srirajaskanthan, L. Marelli, A. Karpathakis, C. Toumpanakis, T. Meyer, J. Buscombe, M.Dusmet, M.E.Caplin. Bronchial carcinoid tumours: Clinical features and management in a series of 45 patients. UKINET 2007- 2nd Prize.

  55. Krepska, A. Davidson, R. Srirajaskanthan, C.Toumpanakis, T. Meyer, A. Mayer, Caplin M. Presentation and diagnostic features of Pancreatic Endocrine Tumours. Gastroenterology 2007. 132:4(supp 1): A310

  56. Toumpanakis, A.M Quigley, R. Srirajaskanthan, A. Karpathakis, A. Krepska, T. Meyer, J. Buscombe, M.E Caplin. Encouraging results with the somatostatin analogue 90-yttrium-dota-octreotate for the treatment of metastatic neuroendocrine tumours: A series of 47 patients. Gastroenterology 132:4(supp 1): A30

  57. Toumpanakis, A.M Quigley, R. Srirajaskanthan, A. Karpathakis, A. Krepska, T. Meyer, J. Buscombe, M.E Caplin. The new radiolabelled somatostatin analogue 90-yttrium-dota-octreotate for the treatment of metastatic neuroendocrine tumours: initial results and tolerability in a series of 47 patients. Gut 56: A43.

  58. R. Srirajaskanthan, C. Toumpanakis, A. Karpathakis, T. Meyer, J. Buscombe, M. Dusmet, M.E Caplin (2007). Bronchial carcinoid tumours: clinical features and management in a series of 41 patients. ENET 2007.

  59. R. Srirajaskanthan, K. Chong, P. Mairs. Polypectomy and adenoma pick-up rate within a district general hospital. South Thames regional BSG meeting, 2006

  60. R. Srirajaskanthan, K. Manoj, A.F Muller, SGB Barton. Rapid access endoscopy service at Kent and Canterbury hospital. South Thames regional BSG meeting, 2006

  61. M.C.Y Wong, E. Lynn, R. Hunter, R. Srirajaskanthan, V.R Preedy, H. Wiseman (2005) The mRNA levels of brain antioxidant enzymes in supplemental antioxidant therapy: a comparison of phyto-oestrogens and α-tocopherol. Proceedings of the Nutrition Society [Abstract, 64:97A]

  62. M.C.Y Wong, E. Lynn, R. Hunter, R. Srirajaskanthan, V.R Preedy, H. Wiseman (2005) The effect of acute alcohol dosage on the perturbation of antioxidant capacity in the rat liver. Proceedings of the Nutrition Society [Abstract,64:95A]

  63. Wong M.C.Y., Hunter R., Srirajaskanthan R., Trick K., L’Abbe M.R., Preedy V.R., Wiseman H. (2005) To what extent is in liver antioxidant capacity changed by acute ethanol dosage? Alcohol and Alcoholism [Abstract, 40 (suppl 1):i33]

  64. R. Srirajaskanthan, R.J Hunter, M.  Koll, V.R Preedy.  Alcohol affects SERCA content and phosphorylation of phospholamban in rat hearts. Alcoholism: 28(8) Supplement:14A, August 2004.

  65. M.C.Y Wong, E. Lynn, R. Hunter, R. Srirajaskanthan, V.R Preedy, H. Wiseman. (2004) Is the FRAP assay a good marker of oxidative stress in laboratory animals? Proceedings of the Nutrition Society [Abstract, 63:89A].

  66. R. Srirajaskanthan, R.J Hunter, Koll, V.R Preedy. Alcohol affects SERCA content and phosphorylation of phospholamban in rat hearts. Alcohol and alcoholism (Alcohol and Alcoholism, 2004).

  67. R. Srirajaskanthan, M. Ostermann, D.G Goldsmith. Renal arterial intervention then sustained use of ACE/ARB in ARAS can be a safe and effective treatment for refractory ARAS-hypertension. Nephrology, dialysis and Transplantation journal. 2003. Supplement4: pg 628.

  68. R. Srirajaskanthan, M. Ostermann, D. Goldsmith. Renal arterial intervention to permit sustained use of ACEI/ARB in ARAS is a safe and effective treatment for ARAS-hypertension. Journal of renovascular disease 2003. Volume 2.

  69. R. Srirajaskanthan, M. Sriharan, P. Bhamra-Ariza, W.E Park, R.S Bakri, H.S Seetho, D.G Goldsmith. Blood pressure control targets are more rarely achieved than lipid-reduction targets in cardiovascular prevention strategies for renal transplant patients. American Journal of Nephrology abstract, 2002.

  70. M. Sriharan, R. Srirajaskanthan, P. Bhamra-Ariza, E.W Park, R.S Bakri, V.H Seetho, D.G Goldsmith. Immunosuppressive drugs are a major cause of long-term cardiovascular risk elevation. Autumn UK renal association meeting, 2002.

  71. P. Bhamra-Ariza, W.E Park, R.S Bakri, M. Sriharan, R. Srirajaskanthan, H.V Seetho, D.G Goldsmith. Atorvastatin monotherapy is a safe and effective way to treat post renal transplantation dyslipidaemia. Autumn UK renal association meeting, 2002.